Quest Diagnostics now offers BRCAvantage Plus™ expanded testing for significant breast cancer susceptibility genes.
Why test beyond BRCA1 and BRCA2?
While mutations in BRCA1 and BRCA2 may explain 15-20% of hereditary breast cancer cases1, TP53, PTEN, CDH1, STK11 and PALB2 have also been described as high penetrance cancer susceptibility genes and together explain an additional 3.0-4.5% of hereditary breast cancers.
This complimentary, web-based program, supported by an independent medical education grant from Quest Diagnostics, provides clinicians with the opportunity to earn CME credit while learning how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in the diagnosis and management of breast cancer.
Quest Diagnostics is the world’s leading provider of diagnostic information services that patients and clinicians need to make better health care decisions.
More than half a million patients every day—nearly 150 million patients every year—benefit from our solutions and commitment to creating a healthier world.
We are focused on providing access to testing with our extensive capabilities and services that make testing easier and more affordable.
BRCAvantage™ combines testing expertise with extensive support services to deliver results you can trust: